{
    "ticker": "TARS",
    "name": "Tarsus Pharmaceuticals, Inc.",
    "description": "Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for eye diseases and other conditions. Founded in 2018, Tarsus aims to transform the treatment landscape for patients suffering from unmet medical needs. The company is known for its lead product, TP-03, which is being developed as a once-daily topical treatment for Demodex blepharitis, a common condition affecting the eyelids. By leveraging its proprietary drug delivery technology, Tarsus is creating therapies that minimize side effects and enhance patient compliance. The company's commitment to advancing eye care is underscored by its robust pipeline of product candidates that are designed to address various ocular conditions. Tarsus is dedicated to conducting rigorous clinical trials to ensure the safety and efficacy of its products, ultimately striving to improve the quality of life for patients. In addition to its focus on eye diseases, Tarsus is exploring potential applications of its technology in other therapeutic areas, further broadening its impact in the pharmaceutical industry. With a passionate team and strong scientific backing, Tarsus is positioned to be a leader in the development of innovative therapies for patients worldwide.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Los Angeles, California, USA",
    "founded": "2018",
    "website": "https://www.tarsusrx.com",
    "ceo": "Bobak Azamian",
    "social_media": {
        "twitter": "https://twitter.com/TarsusRx",
        "linkedin": "https://www.linkedin.com/company/tarsus-pharmaceuticals/"
    },
    "investor_relations": "https://ir.tarsusrx.com",
    "key_executives": [
        {
            "name": "Bobak Azamian",
            "position": "CEO"
        },
        {
            "name": "Michael McGarrity",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Ocular Therapeutics",
            "products": [
                "TP-03"
            ]
        }
    ],
    "seo": {
        "meta_title": "Tarsus Pharmaceuticals, Inc. | Innovative Ocular Therapies",
        "meta_description": "Explore Tarsus Pharmaceuticals, Inc., a leader in developing innovative treatments for eye diseases. Learn about the company's pipeline and commitment to patient care.",
        "keywords": [
            "Tarsus Pharmaceuticals",
            "Eye Care",
            "Biotechnology",
            "Ocular Therapies",
            "TP-03",
            "Pharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What is Tarsus Pharmaceuticals known for?",
            "answer": "Tarsus Pharmaceuticals is known for developing innovative treatments for eye diseases, particularly its lead product TP-03 for Demodex blepharitis."
        },
        {
            "question": "Who is the CEO of Tarsus Pharmaceuticals?",
            "answer": "Bobak Azamian is the CEO of Tarsus Pharmaceuticals, Inc."
        },
        {
            "question": "Where is Tarsus Pharmaceuticals headquartered?",
            "answer": "Tarsus Pharmaceuticals is headquartered in Los Angeles, California, USA."
        },
        {
            "question": "What are Tarsus's main products?",
            "answer": "Tarsus's main product is TP-03, which is in development for the treatment of Demodex blepharitis."
        },
        {
            "question": "When was Tarsus Pharmaceuticals founded?",
            "answer": "Tarsus Pharmaceuticals was founded in 2018."
        }
    ],
    "competitors": [
        "AMGN",
        "REGN",
        "VRTX",
        "BMY"
    ],
    "related_stocks": [
        "PFE",
        "JNJ",
        "MRK",
        "ABBV"
    ]
}